tiprankstipranks
ImmunityBio (IBRX)
NASDAQ:IBRX

ImmunityBio Stock Price & Analysis

493 Followers

IBRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.60 - $10.69
Previous Close$4.65
Volume1.51M
Average Volume (3M)1.59M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$80.37M
Total Debt (Recent Filing)$316.27M
P/E Ratio-4.9
Beta0.36
Next EarningsNov 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.95
Shares Outstanding400,304,106
R-Squared0.07
Standard Deviation0.32
10 Day Avg. Volume3,549,838
30 Day Avg. Volume1,589,087
P/B Ratio-4.43
P/S Ratio3939.63
P/CF RatioN/A
P/FCF Ratio-4.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside60.97% Upside
Rating ConsensusModerate Buy
Alpha0.02
Number of Analyst Covering1


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

IBRX FAQ

What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $2.60 and its highest was $10.69 in the past 12 months.
    What is ImmunityBio’s market cap?
    Currently, no data Available
    When is ImmunityBio’s upcoming earnings report date?
    ImmunityBio’s upcoming earnings report date is Nov 11, 2022 which is in 44 days.
      How were ImmunityBio’s earnings last quarter?
      ImmunityBio released its earnings results on Aug 08, 2022. The company reported -$0.24 earnings per share for the quarter, the consensus estimate of -$0.24 by $0.
        Is ImmunityBio overvalued?
        According to Wall Street analysts ImmunityBio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ImmunityBio pay dividends?
          ImmunityBio does not currently pay dividends.
          What is ImmunityBio’s EPS estimate?
          ImmunityBio’s EPS estimate is -$0.23.
            How many shares outstanding does ImmunityBio have?
            ImmunityBio has 400,304,100 shares outstanding.
              What happened to ImmunityBio’s price movement after its last earnings report?
              ImmunityBio reported an EPS of -$0.24 in its last earnings report, expectations of -$0.24. Following the earnings report the stock price went down -0.445%.
                Which hedge fund is a major shareholder of ImmunityBio?
                Among the largest hedge funds holding ImmunityBio’s share is Harbourvest Partners Llc. It holds ImmunityBio’s shares valued at 1M.

                  ---

                  ImmunityBio Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  6
                  The ImmunityBio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  ImmunityBio

                  NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis